

UPCOMING VIB CONFERENCES & EVENTS

27-28
Oct 2021

New Horizons in Alzheimer's Disease
Virtual & Leuven - Belgium - #NHAD21

22-23
Nov 2021

Translational Immunology
Ghent - Belgium - #TransImmu21

10-11
Mar 2022

Applied Bioinformatics in Life Sciences (4th edition)
Leuven - Belgium - #ABLS22

30-31
May 2022

Next-Generation Protein Analysis and Detection (4th edition)
Ghent - Belgium - #NGPAD22

16-17
Jun 2022

Recent insights into Immuno-Oncology
Leuven - Belgium - #ImmunoOnco22

17-19
Aug 2022

4th International Brassinosteroid Conference
Ghent - Belgium - #BRconf2022

21-23
Sep 2022

The Leuven Protein Aggregation Meeting
Leuven - Belgium - #ProAgg22

Hybrid edition New Horizons in Alzheimer's Disease

27-28 OCTOBER, 2021 | LEUVEN, BE

www.vibconferences.be

 #NHAD21

WWW.VIBCONFERENCES.BE

VIB
Rijvischestraat 120
9052 Gent, Belgium

Tel: +32 9 244 66 11
Fax: +32 9 244 66 10
conferences@vib.be

WELCOME

Dear conference participant,

On behalf of the organizing committee, it is our pleasure to welcome you to the hybrid edition of New Horizons in Alzheimer's Disease.

As you know Alzheimer's Disease research is accelerating with exciting new insights into molecular and cellular mechanisms. This upcoming conference brings together some of the thought leaders in the field with young investigators to stimulate discussion and interaction.

We anticipate further insights into the triangle amyloid, Tau and neuroinflammation and how these might provide novel therapeutic approaches.

The following topics will be the focus of this conference:

- Genes and environment
- Synapse and circuitry
- Seeds and spreading of disease
- Mechanisms and models of disease

To support upcoming scientists and provide them with the opportunity to present their research, we have included thirteen shorter talks in the program, which were selected from submitted abstracts, as well as offer the opportunity for further interactions at poster sessions.

On the first conference evening we'll welcome Roger M Nitsch, CEO & President of Neurimmune and inventor of aducanumab, who will give a keynote lecture on the discovery of aducanumab for the potential treatment of Alzheimer's Disease.

Next to an inspiring scientific program, you will have ample networking opportunities (both live and virtual) during the breaks, poster sessions and the conference dinner.

Finally, we would like to thank our sponsors for supporting this event. You can visit their on-site and virtual booths during the entire event.

We wish you all an inspiring and productive conference.

Organizing Committee

Wim Annaert, VIB-KU Leuven Center for Brain & Disease Research, BE

Jean-Pierre Brion, ULB Neuroscience Institute, BE

Lucía Chávez Gutiérrez, VIB Center for Brain and Disease Research, BE

Bart De Strooper, VIB-KU Leuven Center for Brain & Disease Research, BE & UK Dementia Research Institute, UK

Ilse Dewachter, Hasselt University, BE

Rosa Rademakers, VIB-UAntwerp Center for Molecular Neurology, BE

Patrik Verstreken, VIB-KU Leuven Center for Brain & Disease Research, BE

Roosmarijn Vandenbroucke, VIB-UGent Center for Inflammation Research, BE

Evy Vierstraete, Science Events Manager, VIB, BE

CORPORATE PARTNERS

The 2021 VIB Conference Series is kindly supported by the following corporate partners:



PROGRAM | WEDNESDAY 27 OCTOBER

- 08:30 - 08:50 Registration & coffee
- 08:50 - 09:00 Welcome by Bart De Strooper

Session 1

GENES AND ENVIRONMENT

Chairs: Rosa Rademakers & Ilse Dewachter

- 09:00 - 09:30 Relevance of novel genes identified in families with neurodegenerative brain diseases
Christine Van Broeckhoven, *VIB-UAntwerp Center for Molecular Neurology, BE. Supported by SAO.*
- 09:30 - 10:00 Decoding microglia phenotypes in health and disease
Christopher Glass, *University of California, San Diego, US*
- 10:00 - 10:30 Learning from cognitively healthy centenarians to escape dementia
Henne Holstege, *Amsterdam UMC & Amsterdam Alzheimer Center, NL*
- 10:30 - 10:40 *Selected Talk* Stem-cell-derived human microglia transplanted in mouse brain to study human disease
Poster #32 **Nicola Fattorelli**, *VIB-KU Leuven Center for Brain & Disease Research, BE*
- 10:40 - 10:50 Microbiota-derived short chain fatty acids modulate microglia and promote A β plaque deposition
Poster #99 **Sabina Tahirovic**, *German Center for Neurodegenerative Diseases (DZNE), DE*
- 10:50 - 11:20 Coffee
- 11:20 - 11:50 Molecular basis of familial Alzheimer's disease: insights into disease mechanisms and implications for therapeutics
Lucía Chávez Gutiérrez, *VIB Center for Brain and Disease Research, BE. Supported by SAO.*
- 11:50 - 12:20 Modulation of Amyloid Deposition and Neuroinflammation by the Microbiome
Sangram S. Sisodia, *Department of Neurobiology, University of Chicago, US*

- 12:20 - 12:50 Glial disease and aging confer competitive disadvantage: A basis for cell replacement as a therapeutic strategy in neurodegenerative disorders
Steven A. Goldman, *University of Rochester, Medical Center, US & University of Copenhagen, DK*
- 12:50 - 13:00 *Selected Talk*: New regulators of amyloid β -peptide toxicity in Alzheimer's disease
Poster #73 **Francisco Muñoz**, *Universitat Pompeu Fabra, ES*
- 13:00 - 13:05 *Company pitch*: 3D light sheet microscopy of entire mouse brain
Veerle Lemmens, *Imaging Specialist BeNeLux Miltenyi Biotec, BE*
- 13:05 - 13:45 Lunch
- 13:45 - 14:30 On-site Poster Session

Session 2

SYNAPSE AND CIRCUITRY

Chairs: Patrik Verstreken & Jean-Pierre Brion

- 14:30 - 15:00** Novel insights into the role of the APP family in maintaining neural circuit function, with implications for AD therapy
Marc Aurel Busche, *UK Dementia Research Institute at UCL, UK*
- 15:00 - 15:30** SYNGO: defining the synapse and synaptic pathways in brain disease
Matthijs Verhage, *Vrije Universiteit & Amsterdam University Medical Center, NL*
- 15:30 - 16:00** Neural Basis of a Silent Alzheimer's Disease Phase
Inna Slutsky, *Tel Aviv University, IL*
- 16:00 - 16:30** Coffee
- 16:30 - 16:40** *Poster #58* **Selected Talk:** Lowering Synaptogyrin-3 expression rescues Tau-induced memory defects and synaptic loss in the presence of microglial activation
Pablo Largo Barrientos, *VIB-KU Leuven Center for Brain & Disease Research & KU Leuven, Department of Neurosciences, Leuven Brain Institute, Mission Lucidity, BE*
- 16:40 - 16:50** *Poster #93* **Selected Talk:** Astrocytes and functional network disruptions at early stages of amyloid pathology
Disha Shah, *VIB-KU Leuven Center for Brain & Disease Research, BE*
- 16:50 - 17:00** *Poster #89* **Selected Talk:** In vivo assessment of synaptic pathology in dementia with SV2A-PET
Eric Salmon, *University of Liege / GIGA Cyclotron Research Centre, BE*

- 17:00 - 17:30** Gamma oscillations: mechanisms, function and human diseases
Li-Huei Tsai, *The Picower Institute for Learning and Memory & MIT, US*
- 17:30 - 18:00** Imaging synaptic changes in Alzheimer's disease
Tara Spire-Jones, *The University of Edinburgh & UK Dementia Research Institute, UK*
- 18:00 - 19:00** Walk to Kinopolis Leuven, followed by a welcome drink
- 19:00 - 20:00** The discovery of aducanumab for the potential treatment of Alzheimer's disease
Roger M Nitsch, *CEO & President, Neurimmune, CH*
- 20:15 - 22:30** Conference dinner at Kinopolis Leuven

08:30 - 09:00 Welcome coffee

Session 3

SEEDS AND SPREADING OF DISEASE

Chairs: Ilse Dewachter & Roos Vandenbroucke

- 09:00 - 09:30** Fluid biomarkers and their relation to Alzheimer brain pathology
Mathias Jucker, *The Hertie Institute for Clinical Brain Research (HIH) & German Center for Neurodegenerative Diseases (DZNE), DE*
- 09:30 - 10:00** New cell model for FTD tauopathy
Karen Duff, *UK Dementia Research Institute at UCL, UK*
- 10:00 - 10:30** Seeding and spreading in tauopathies: mechanisms and therapeutic approaches
Luc Buée, *University of Lille, Inserm, CHU-Lille, FR*
- 10:30 - 10:35** Company pitch: WuXi AppTec: Your partner for Alzheimer's Disease drug discovery
Kris Rutten, *Director, WuXi AppTec, NL*
- 10:35 - 11:05** Coffee
- 11:05 - 11:15** *Poster #54* Selected Talk: Heterotypic Abeta interactions facilitate amyloid assembly and modify amyloid structure
Frederic Rousseau, *Switch Laboratory, VIB-KU Leuven Center for Brain & Disease Research, BE*
- 11:15 - 11:25** *Poster #74* Selected Talk: Disassembly of Tau fibrils by the human Hsp70 disaggregation machinery generates small seeding-competent species
Eliaana Nachman, *VIB-KU Leuven Center for Brain & Disease Research, BE*
- 11:25 - 11:35** *Poster #70* Selected Talk: Conformational strain diversity in misfolded amyloid beta peptides and potential repercussions in Alzheimer's pathology
Rodrigo Morales, *The University of Texas Health Science Center at Houston, US*

- 11:35 - 12:05** The Glymphatic System
Maiken Nedergaard, *University of Rochester, Medical Center, US & University of Copenhagen, DK*
- 12:05 - 12:35** The cellular phase of Alzheimer's disease
Bart De Strooper, *VIB-KU Leuven Center for Brain & Disease Research, BE & UK Dementia Research Institute, UK*
- 12:35 - 13:15** Lunch
- 13:15 - 14:00** Virtual Poster Session

Session 4

MECHANISMS AND MODELS OF DISEASE Chairs: Lucía Chávez Gutiérrez & Wim Annaert

- 14:00 - 14:30** Beyond microglia: Temporal sequencing of perturbations in human cellular communities to establish the causal chain leading to aging-related cognitive decline
Philip L. De Jager, *Division of Neuroimmunology & Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University Medical Center, US*
- 14:30 - 15:00** Impaired SorLA maturation and trafficking as a new mechanism for SORL1 missense variants in Alzheimer disease
Anne Rovelet-Lecrux, *University of Rouen, Inserm UMR1245, FR*
- 15:00 - 15:30** Direct neuronal reprogramming to study aging and age-related neurodegeneration
Jerome Mertens, *Salk Institute for Biological Studies, US & University of Innsbruck, AT*
- 15:30 - 15:40** *Poster #103* **Selected Talk:** Combining pathogenic Tau pathways generates a super toxic Tau
Valerie Uytterhoeven, *VIB-KU Leuven Center for Brain & Disease Research, BE*
- 15:40 - 15:50** *Poster #90* **Selected Talk:** Generation of non-human primate models of Alzheimer's disease
Hiroki Sasaguri, *RIKEN Center for Brain Science, JP*
- 15:50 - 16:20** Coffee break
- 16:20 - 16:30** *Poster #27* **Selected Talk:** Microglial contributions along the ATN axis in AD in preclinical models
Ilse Dewachter, *Hasselt University, BE*



- 16:30 - 16:40** *Poster #110* **Selected Talk:** Developing human cellular models to understand biological mechanisms linked to AD genetic risk
Jessica Young, *University of Washington, US*
- 16:40 - 17:10** Systemic regulation of brain function at the vasculature
Tony Wyss-Coray, *Stanford University, US*
- 17:10 - 17:40** Redefining Microglia States and Function in Alzheimer's Disease
Beth Stevens, *FB Kirby Neurobiology Center; Boston Children's Hospital & Broad Institute Member, US*
- 17:40 - 18:10** Update on fluid biomarkers for Alzheimer's disease
Henrik Zetterberg, *University of Gothenburg, SE & UK Dementia Research Institute, UK*
- 18:10 - 18:25** Poster prize ceremony and closing remarks by Bart De Strooper

POSTER ABSTRACTS

Abstracts ordered by first author. Presenting authors are highlighted in orange.

Posters marked with a  were selected for a short talk.

#	Name	Institute	Page nr.
01	Emmanuel Adewuyi	Centre for Precision Health, Edith Cowan University, AU	74
02	Lotta Agholme	University of Gothenburg, SE	75
03	Mhd Aghyad Al Kabbani	Uniklinik Köln, DE; Center of Molecular Medicine Cologne, DE	76
04	Kunie Ando	Université Libre de Bruxelles, ULB Neuroscience Institute, BE	77
05	Sarah Bachmann	Institute of Human Genetics, & CMMC, University Hospital Cologne, DE	78
06	Karissa Barthelson	The University of Adelaide, AU	79
07	Viktoriia Bavykina	Université de Sherbrooke, CA	80
08	Paula Beltran-Lobo	King's College London, UK	81
09	Mireia Bernuz	Universitat Autònoma de Barcelona, ES	82
10	Maria Bichmann	BioMedX Institute, DE	83
11	Pablo Botella Lucena	Biomedical Research Institute, Hasselt University, BE	84
12	Vangelis Bouris	DZNE, DE; University of Tübingen, DE	85
13	Sara Calafate	VIB-KU Leuven CBD, BE; Leuven Brain Institute, BE	86
14	Manon Callens	KU Leuven, BE	87
15	Alessia Caramello	UK DRI - Imperial College London & University College London, UK	88
16	Grazia I Caruso	University of Catania, IT	89
17	Erika Cecon	Institut Cochin, Inserm U1016, CNRS UMR 8104, Université de Paris, FR	90
18	Yun-Ru Chen	Academia Sinica/ Genomics Research Center, TW	91
19	Claudia Colussi	National Research Council, IASI, IT	92
20	Lien Cools	KU Leuven, Department of Biology, BE; Leuven Brain Institute, BE	93
21	Marcos Costa	Institut Pasteur de Lille, FR; Brain Institute, UFRN, BR; INSERM U1167, FR	94
22	Katrine Dahl Bjørnholm	Karolinska Institutet, SE	95
23	Angelika Dannert	University Hospital, & LMU Munich, DE	96
24	Marie-Ange de Fisenne	Université Libre de Bruxelles (ULB), BE	97
25	Marie-Ange de Fisenne	Université Libre de Bruxelles (ULB), BE	98
26	Aurore Delvenne	Maastricht University, NL	99
 27	Ilse Dewachter	Biomedical Research Institute, Hasselt University, BE	100
28	Emilie Doeraene	Université Libre de Bruxelles, ULB Neuroscience Institute (UNI), BE	101

#	Name	Institute	Page nr.
29	Kim Dore	University of California, San Diego, US	102
30	Pieter Dujardin	Welcome to the VIB-UGent Center for Inflammation Research, BE	103
31	Bianca Eßwein	Institute of Developmental Genetics, Helmholtz Zentrum München, DE	104
 32	Nicola Fattorelli	VIB-KU Leuven CBD, BE; Leuven Brain Institute, KU Leuven, BE	105
33	Sonja Fixemer	LCSB, University of Luxembourg, LU; LCNP, LU	106
34	Eyleen L.K. Goh	Lee Kong Chian School of Medicine, SG	107
35	Gilad S. Green	ELSC, Hebrew University, IL	108
36	Iris Grgurina	UMR6473/CNRS - University of Strasbourg, FR	109
37	Francesc Guix	Centro de Biología Molecular Severo Ochoa / CSIC-UAM, ES	110
38	Sara Gutierrez Fernandez	VIB center for brain & disease research, BE	111
39	Martina Hallegger	Francis Crick Institute, GB; Institute of Neurology, UCL, UK	112
40	Silva Hecimovic	Ruder Boskovic Institute, Division of Molecular Medicine, Zagreb, HR	113
41	Helene Hirbec	IGF, CNRS, INSERM, Univ. Montpellier, Montpellier, FR	114
42	Yael Hirschberg	VITO, BE; UAntwerp, BE	115
43	Kelly Hodonou	Inserm U1167, Institut Pasteur de Lille, Université de Lille, FR	116
44	Zengjin Huang	VIB Center for Brain & Disease Research, BE; KU Leuven, BE	117
45	Christiaan F.M. Huffels	Brain Center University Medical Center Utrecht, NL	118
46	Lianne Hulshof	University Medical Center Utrecht Brain Center, Utrecht University, NL	119
47	Akihiro Iguchi	Graduate School of Pharmaceutical Sciences, The University of Tokyo, JP	120
48	Richeng Jiang	Karolinska Institutet, SE	121
49	Nobuto Kakuda	Doshisha University, JP	122
50	Julien Klimmt	LMU Munich, DE; Graduate School of Systemic Neurosciences Munich, DE	123
51	Matthias Koch	VIB-KU Leuven Center for Brain & Disease Research, BE	124
52	Sabine C Konings	Lund University, SE	125
53	Katerina Konstantoulea	KU Leuven, BE; VIB Center for Brain and Disease Research, BE	126
 54	Katerina Konstantoulea	KU Leuven, BE; VIB Center for Brain and Disease Research, BE	127
55	Andreea-Claudia Kosa	ULB Neuroscience Institute (UNI), Faculty of Medicine, ULB, BE	128
56	Philipp Koulousakis	Maastricht University, NL; Hasselt University, NL	129

#	Name	Institute	Page nr.
57	Josephine Labus	Cellular Neurophysiology/ Hannover Medical School, DE	130
58	Pablo Largo-Barrientos	VIB-KU Leuven CBD, BE; Leuven Brain Institute, Mission Lucidity, BE	131
59	Victor Lau	University of Victoria, CA	132
60	Isaac Llorente Saguer	UCL, UK	133
61	Chritica Lodder	Biomedical Research Institute, Hasselt University, BE	134
62	Lidia Lopez Gutierrez	ULB Neuroscience Institute (UNI), Université Libre de Bruxelles, BE	135
63	Emma Luckett	KU Leuven, BE; LBI, Leuven, BE; Laboratory for Complex Genetics, KU Leuven, BE	136
64	Riki Maruyama	Osaka University, JP	137
65	Mark Maskery	Lancaster University, Lancaster Medical School, UK	138
66	Bruna Mata Soares	Institut Pasteur de Lille, FR	139
67	M. Mejias-Ortega	IBIMA, Facultad de Cienc, ES; CIBERNED, Madrid, ES	140
68	Ana Raquel Melo de Farias	Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1167, FR	141
69	Farzaneh Mirfakhari	CEDOC-Chronic Diseases Research Center-NOVA Medical School-lisbon, PT	142
70	Rodrigo Morales	The University of Texas Health Science Center at Houston, US	143
71	Omar Mossad	Faculty of Medicine, & Faculty of Biology, University of Freiburg, DE	144
72	Darrell Mousseau	University of Saskatchewan, CA	145
73	Francisco Muñoz	Universitat Pompeu Fabra, ES	146
74	Eliana Nachman	ZMBH & DKFZ, DE; Present address: VIB KU Leuven CBD, BE	147
75	Michael Ohlmeyer	Atux Iskay LLC, US	148
76	Dean Paes	Hasselt University, BE; Maastricht University, NL	149
77	Isabel Paiva	LNCA CNRS UMR 7364, Université de Strasbourg, FR	150
78	Noa Peeleman	KU Leuven, BE	151
79	Javier M. Peralta Ramos	Department of Neurobiology, Weizmann Institute of Science, IL	152
80	Anika Perdok	VIB Center for Brain & Disease Research, BE	153
81	Pol Picón-Pagès	Faculty of Health and Life Sciences, Universitat Pompeu Fabra, ES	154
82	Pranav Preman	VIB Center for Brain & Disease Research, BE; LBI, KU Leuven, BE	155
83	Roya Ramezankhani	KU Leuven, BE	156
84	Ana Rastija	Ruder Boskovic Institute, HR	157
85	Ben Rombaut	Hasselt University, BE; Maastricht University, BE	158
86	Sandra Roselli	Dept. of Psychiatry and Neurochemistry, University of Gothenburg, SE	159
87	Marvin Ruiters	Utrecht University, NL	160
88	Isabel Salas	Salk Institute, US	161
89	Eric Salmon	University of Liege / GIGA Cyclotron Research Centre, BE	162
90	Hiroki Sasaguri	RIKEN Center for Brain Science, JP	163
91	Marie Schützmann	Institut für Physikalische Biologie, Heinrich Heine University, DE	164
92	Dag Sehlin	Uppsala University, SE	165
93	Disha Shah	VIB center for Brain and Disease Research, VIB-KU Leuven, BE	166
94	Dolores Siedlecki-Wullich	Université de Lille; Institut Pasteur de Lille; CHU Lille; INSERM U1167; LabEx DISTALZ, FR	167
95	Annerieke Sierksma	VIB - KU Leuven Center for Brain and Disease Research, BE	168

#	Name	Institute	Page nr.
96	Lena Spieth	Max Planck Institute of Experimental Medicine, DE	169
97	Jing SU	Research Service Division, WuXi AppTec Co. Ltd., Shanghai, CN	170
98	Takanobu Suzuki	Neuropathology and Neuroscience, The university of Tokyo, JP	171
99	Sabina Tahirovic	German Center for Neurodegenerative Diseases (DZNE), DE	172
100	Betty Tijms	Alzheimer Center Amsterdam, Amsterdam UMC, NL	173
101	Ajit Tiwari	Molecular Physiology and Biophysics, University of Virginia, US	174
102	Larissa Traxler	University of Innsbruck, AT; The Salk institute of Biological Studies, US	175
103	Valerie Uytendaele	VIB/KU Leuven, BE	176
104	Zoë Van Acker	VIB-KU Leuven Center for Brain & Disease Research, BE	177
105	Charysse Vandendriessche	VIB Center for Inflammation Research, VIB/Ghent, BE; Ghent University, BE	178
106	Marloes Verkerke	Dept Translational Neuroscience, Brain Center, UMC Utrecht, NL	179
107	Rosanne Wouters	VIB, BE; KU Leuven, BE	180
108	Yessica Wouters	VIB Center for Brain & Disease Research, BE; Technical University of Denmark, DK	181
109	Miyabishara Yokoyama	Graduate School of Pharmaceutical Sciences, The University of Tokyo, JP	182
110	Jessica Young	University of Washington, US	183
111	Yichen Zhou	Department of Microbiology, Monash University, AU	184
112	Lucia Zhou-Yang	Institute of Molecular Biology, CMBI, Leopold-Franzens-University, AT	185

TAU-MISSORTING BASED LOSS OF MICROTUBULES IN HUMAN MODEL SYSTEMS

Mhd Aghyad Al Kabbani^{1,2}

¹Institute of Human Genetics, Uniklinik Köln, Germany, DE; ²Center of Molecular Medicine Cologne, DE

TAU is a neuronal microtubule-associated protein that is missorted and aggregated in an array of diseases known as tauopathies, including Alzheimer disease (AD). Microtubules are essential for neuronal function, but in AD neuronal microtubules are lost, the cause is unclear. TTLs are a class of enzymes that regulate microtubule dynamics and stability via specific post translational modifications of microtubules, of which polyglutamylation leads to subsequent recruitment of SPASTIN and other microtubule severing enzymes.

In AD-paradigms in cell and animal models, missorted TAU recruits TTL6 to the dendrites, inducing microtubule polyglutamylation and SPASTIN-mediated microtubule loss. In this study, we aim to study the interrelationship between TAU and different TTLs and their role in microtubule loss in TAU-missorting based, human-disease relevant systems, and test the therapeutic potential of manipulating TTLs and related proteins such as SPASTIN.

We will use iPSC-derived human neurons, primary mouse neurons and TAU transgenic mice expressing human disease-relevant TAU (P301L-TAU or all 6 human TAU-isoforms) to investigate the activities of TAU, SPASTIN and TTLs in disease paradigms. We will manipulate TAU, SPASTIN and TTLs via overexpression/knockdown and study the subsequent effects on microtubules, TAU and neuronal cell physiology.

We will provide first evidence of the disease relevance and druggability of several TTLs, opening up novel therapeutic approaches for AD and related tauopathies.

PICALM REDUCTION EXACERBATES TAU PATHOLOGY IN A MURINE TAUOPATHY MODEL

Kunie Ando¹, Robert De Decker¹, Cristina Vergara¹, Zehra Yilmaz¹, Salwa Mansour¹, Valérie Suain¹, Kristel Slegers², Marie-Ange de Fisenne¹, Sarah Houben¹, Marie-Claude Potier³, Charles Duyckaerts^{3,4}, Toshio Watanabe⁵, Luc Buée⁶, Karelle Leroy¹, Jean-Pierre Brion¹

¹Laboratory of Histology, Faculty of Medicine, Université Libre de Bruxelles, ULB Neuroscience Institute, BE; ²Neurodegenerative Brain Diseases Group, VIB Center for Molecular Neurology, University of Antwerp, Universiteitsplein 1, BE; ³Sorbonne Universités, UPMC Univ Paris 06 UMR S 1127, and Inserm, U 1127, and CNRS UMR 7225, and ICM, Paris, FR; ⁴Laboratoire de Neuropathologie Escourolle, Hôpital de la Pitié-Salpêtrière, AP-HP, FR; ⁵Department of Biological Science, Graduate School of Humanities and Sciences, Nara Women's University, JP; ⁶Univ. Lille, Inserm, CHU-Lille, Alzheimer & tauopathies, LabEx DISTALZ, FR

Genome wide association studies (GWAS) have identified *PICALM* as one of the most significant susceptibility loci for late-onset Alzheimer disease (AD) after *APOE* and *BIN1*. *PICALM* is a clathrin adaptor protein and plays critical roles in clathrin-mediated endocytosis and in autophagy.

In this study, we confirmed a significant reduction of soluble *PICALM* protein and autophagy deficits in the *post-mortem* human brains of FTLD-tau-*MAPT* (P301L, S364S and L266V). We generated a novel transgenic mouse line named Tg30xPicalm+/- by crossing Tg30 tau transgenic mice with Picalm haploinsufficient mice to test whether Picalm reduction may modulate tau pathology. While Picalm haploinsufficiency did not lead to any motor phenotype or detectable tau pathology in mouse brains, Tg30xPicalm+/- mice developed markedly more severe motor deficits than Tg30 by the age of 9 months. Tg30xPicalm+/- had significantly higher

pathological tau levels in the brain, an increased density of neurofibrillary tangles compared to Tg30 mice and increased abnormalities of autophagy markers.


Our results demonstrate that Picalm haploinsufficiency in transgenic Tg30 mice significantly aggravated tau pathologies and tau-mediated neurodegeneration, supporting a role for changes in Picalm expression as a risk/sensitizing factor for development of tau pathology and as a mechanism underlying the AD risk associated to *PICALM*.



The Belgian Alzheimer Foundation is a proud sponsor of the conference New Horizons in Alzheimer's Disease. Our foundation supports Belgian Basic and Clinical Research of Alzheimer's Disease and related dementia. In 2020 the foundation invested € 3,2 million in 17 research projects.

Each year in February we send invitations to all Belgian universities and research institutions to submit research proposals. These proposals are evaluated by a peer-reviewing system driven by our Scientific Advisory Board, so that the best projects are rewarded with a grant.

Standard Grant Applications for a 3-years award period are fixed at € 250.000 and *Pilot Grant Applications* for a 2-years award period are fixed at € 100.000.



The Belgian Alzheimer Foundation is a proud sponsor of the conference New Horizons in Alzheimer's Disease.

Our foundation supports Belgian Basic and Clinical Research of Alzheimer's Disease and related dementia. In 2020 the foundation invested € 3,2 million in 17 research projects.

Each year in February we send invitations to all Belgian universities and research institutions to submit research proposals. These proposals are evaluated by a peer-reviewing system driven by our Scientific Advisory Board, so that the best projects are rewarded with a grant.

Standard Grant Applications for a 3-years award period are fixed at € 250.000 and *Pilot Grant Applications* for a 2-years award period are fixed at € 100.000.

Mark the date!: February the 1st 2022

If you are a scientist working in the field of Basic and Clinical Research of Alzheimer's Disease and related dementia at a Belgian university and you wish to submit a project proposal be aware that we send an invitation to every university with instructions. If you have any questions you can contact us via the email below.

Stichting Alzheimer Onderzoek / Fondation Recherche Alzheimer

Information scientific: scientific.secretariat@stopalzheimer.be

President of the Scientific Advisory Board:

Professor Wim Annaert. Members: Jean-Pierre Brion, Lucia Chavez- Gutierrez, Ilse Dewachter, Sebastiaan Engelborghs, Jean-Noël Octave, Laurence Ris and Eric Salmon